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ABSTRACT
The complex between the macrocyclic ligand DOTA and the metal gadolinium (Gd3+) has been
used as the contrast agent for the MRI T1 weighed imaging. Mono substitution on the tetraaza ring
of DOTA ligand results in the formation of the two distinct complexes that are regioisomers of
each other and they have different contrast efficiency as well as stability. These regioisomers are
only separated by HPLC. With two bulky substituents on the tetraaza ring, it is expected to increase
the selectivity of what regioisomers will be formed for each di-substituting pattern since the
conformation with the least steric hindrance will be favored most to maintain the stability of the
ring structure. This will simplify the synthesis procedure by removing the separation of the
different regioisomers. The contrast efficiency and stability of the complexes made from these new
ligands will also need to be explored. Based on the special characteristics of the DOTA’s tetraaza
ring, three di-substitution patterns will be studied are 2,8-S,S, 2,9-S,S, and 2,5-S,S. This paper’s
goal is to report the synthesis progress of these three patterns. The synthesis includes four main
stages: dibenzyl polypeptide chain, dibenzyl tetra amine chain, dibenzyl tetraaza cyclododecane,
and dibenzyl DOTA. Cyclization in the third stage is crucial to control the di-substitution patterns.
The identity of the product in each step was verified by using 1H-NMR and mass spectrometry.
Pattern 2,9-S,S passed the first two stages and its dibenzyl tetraamine chain needs to be purified
before entering the cyclization process. Pattern 2,8-S,S could not be built from the N terminal
(after building the second peptide bonds, the intermediate product had solubility issues.) The first
peptide bond for the pattern 2,5-S,S is still being built from the N terminal.
INTRODUCTION
The use and limitation of DOTA in MRI imaging technique
MRI imaging has been widely used for the diagnosing purposes in the medical fields because this
technique does not require the use of radioactive isotopes and provides high spatial resolution [1]
[2] [3].

Many different scans and contrast levels can be applied until the normal and the abnormal

parts can be observed [4]. Therefore, the role of contrast agents in MRI imaging is very important.
Depending on the texture of the examining area that the appropriate scan sequence is selected [4].
For T1 weighed imaging, gadolinium based contrast agent (GBCA) is used very often. GCBA is a
complex of lanthanide metal ion gadolinium (Gd3+.) The most famous ligand for GBCA is the
macrocyclic DOTA [5] (figure 1.) The function GBCA is to interact with the water molecules in

the examining area to reduce their protons’ T1 time constants. Those time constants reflect the
different relaxation of the protons in different environments and they are assigned with different
color scales. Combining the location and the color scales, the MRI T1 weighed image is formed [6]
[7]

The GBCA complex itself is safe for the human body.
However, if decomplexation happens, the free metal ion
Gd3+, whose radius is 108pm, can displace the metal ion
Ca2+ , whose radius is 114pm. Ca2+ participates in many
biochemical processes of the cells in the human body.
Gd3+can act as a competitive inhibitor of Ca2+ and thus,
disturb these processes

[8].

That is why there is a

growing concern about increasing the stability and thus,
Figure 1: [GdDOTA]- interacts with a water molecule

the safety of GBCA. In order to make Gd3+ favor
staying in the complex, modification on the ligand

structure is necessary. This research focuses on modifying the macrocyclic (or the tetraaza ring)
component of DOTA ligand.
Mono-substitution results stimulated the study of di-substitution
In the past studies, adding a nitro benzyl group on the tetraaza ring of DOTA affects the ability to
form complex with Gd3+ of this new ligand (NB-DOTA.)

[9] [10]

Specifically, when NB-DOTA

interact with Gd3+, a fixed ratio of two distinct complexes are formed

[10].

These complexes are

regioisomer of each other (figure 2.) Depending on the direction when Gd3+ approaches the ligand
that corner or side regioisomers will form

[10].

These regioisomers have different geometry,

stability and energy, and thus, they have different contrast efficiency as showed in table 1[11]. The
most important difference to notice between the two regioisomers is the water residence time (τM)
which is inversely proportional to the water exchange rate since this parameter reflects the
interaction between the GBCA and the water molecules. These regioisomers can only be separated
by HPLC (figure 3.)

[10]

These fascinating results stimulated the further study on the effect of

substitution on DOTA’s tetraaza ring. Therefore, di-substitution became the subject in this study.

If two benzyl substituents are placed on the tetraaza
ring of DOTA, two trends are expected. First, in order
to maintain the stability of the ring, the conformation
having the least steric hindrance will be favored.
Secondly, the presence of the two bulky benzyl
groups reduces the macrocyclic ring’s mobility of the
complex and thus, prevents the conversion between
the isomer forms due to ring flipping. If these two
trends are observed, they can support the hypothesis
that di-substitution can control what type of
regioisomers will be formed and thus, no additional
steps to separate the side and corner regioisomers are
Table 1: Fitting Parameters for the NMRD Profiles of the Corner
and Side Isomers of GdNB-DOTA in Aqueous Solution[11]

needed since only one type will be formed. The three
patterns will be studied and their expected
dominating regioisomers are summarized in figure 4.
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Figure 3: The HPLC Chromatogram of the separation of Corner and
Side [10]
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Figure 2: The tetraaza ring structure of the two regioisomers
created by NB-DOTA ligand

Figure 4: The summary of the three di-substitution patterns on DOTA’s tetraaza ring and their expected complex's regioisomer

For the pattern 2,8-S,S and 2,5-S,S, the benzyl groups are on the same plane so the only way to
minimize steric hindrance is to favor conformation having them in the equatorial positions. Once
the complex is formed, corner regioisomer is more favorable since it has less steric hindrance. For
the case of pattern 2,9-S,S, both corner and side regioisomers are expected but the specific ratio
cannot be predicted since the two benzyl groups are located on the different plane of the ring. This
allows the macrocyclic ring of its complex to have more mobility comparing to the other patterns.
Developing synthesis strategy to control the desired di-substitution patterns
The synthesis of these di-substituted DOTA includes four main stages: dibenzyl polypeptide chain,
dibenzyl tetra amine chain, dibenzyl tetraaza cyclododecane, and dibenzyl DOTA. From the pure
simple amino acids and amine, the dibenzyl peptide chain is built by using the peptide synthesis

techniques. Building the peptide chain is an important stage because it determines the position of
the benzyl substituents on the tetraaza ring in the future. Cyclization in the third stage is necessary
since the substituents need to be located on the tetraaza ring before the pendant arms are added.
However, once the tetraaza ring is closed, the substituents will more likely to be attacked the lone
pairs of the nitrogen atoms. Those nitrogen spots must be saved for the pendant arms to create the
desired DOTA derivative forms. Therefore, the position of the benzyl substituents must be defined
on the precursors of the tetraaza ring. The retro synthesis plan for the three patterns are showed in
the figure 5 below:
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Pattern 2,5-S,S
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Figure 5: The retro synthesis plan for the three proposed patterns
+

2,8-S,S-dibenzyl polypeptide

NH2

Ethylenediamine

Cyclization procedure is based on the method developed by Reed and Weisman [12] to synthesize
cyclen. Figure 6 below summarizes the cyclization process of the pattern 2,9-S,S with R is the
abbreviation of the benzyl group

Figure 6: The summary of the cyclization process for the pattern 2,9-S,S

RESULTS AND DISCUSSION
The progress of pattern 2,8-S,S
The synthesis progress of pattern 2,8-S,S is summarized in figure 7 below:
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Figure 7 The summary synthesis progress of the pattern 2,8-S,S

The polypeptide chain of this pattern (figure 8) could not be built
O
N
NH2 H

H
N

O

O

from the N terminal in the first attempt. The issue with solubility
NH2

already happened after the first peptide bond was built but it was
neglected since the intermediate solid product could not dissolve in

2,8-S,S- polypeptide
Figure 8: 2,8-S,S-dibenzyl
polypeptide

CDCl3, MeOH, H2O or MeCN with some drops of iPr2Net but
DMSO. Using too much DMSO solvent (150mL) during the process

of building the second peptide bond was a big mistake since it required a lot of heat to vaporize
DMSO. Increasing the temperature of the water bath too high lead to the unwanted removal of the

OBn

Boc protection group on the N terminal of Phenylalanine. The product could not be dissolved in
the available organic solvent, therefore, no 1H-NMR nor mass spectrometry analysis could be
done. This solid formed complex with Cu2+ and dissolved in the mixture of H2O and MeOH.
However, the result from the mass spectrometry analysis could not confirm the presence of desired
product. The fact that this solid could form complex with Cu2+ confirmed that there were peptide
bond formed (Amide can form complex with Cu2+) but specifically whether they were the desired
ones or not could not be concluded. The next step for this pattern will be (a) redo the N terminal
using a smaller amount of DMSO or develop a mixture of the different solvents that the
intermediate product can dissolve and (b) trying to build the peptide bonds from the C terminal:
letting Boc-Phe-OSu reacts with ammonium then remove the Boc group and build the next bond.
The progress of pattern 2,9-S,S
The synthesis progress of pattern 2,9-S,S is summarized in figure 9 below:

Figure 9: The summary synthesis progress of the pattern 2,9-S,S

This pattern is easier to synthesize than the other ones. All the desired peptide bonds were built in
one step. After removing the Boc protection group, the polypeptide was successfully reduced to
the desired tetraamine chain. The tetraamine chain is not ready for the cyclization process yet since
is still in the aqueous layer. The 1H-NMR spectrum of the organic layer did not have the aromatic
signal from the benzyl substituents. In addition, the signals from the solvent were much stronger

than the examining compound’s. The protons from the linear chain and the benzyl substituents of
2,9-S,S-dibenzyl tetraamine showed up in the 1H-NMR spectrum of the aqueous layer. However,
this spectrum also contains strong signal from the solvent MeOH. Therefore, the next step will be
developing a HPLC method to purify 2,9-S,S dibenzyl tetraamine chain. The 1H-NMR spectrum
and the mass spectrum of this tetraamine chain are showed in figure 10. The molecular weight of
the target molecule is 326.25 amu. The results from running the mass spec in the positive mode
(M+H+) has a significant high peak of 327.25 and thus, confirmed the presence of 2,9-S,S-dibenzyl
tetraamine chain in the aqueous layer.
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Figure 10: The mass spectrum (left) and the 1H-NMR spectrum (right) of 2,9-S,S dibenzyl tetraamine

The progress of pattern 2,5-S,S
The synthesis progress of pattern 2,5-S,S is summarized in figure 11 below:
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Figure 11: The synthesis progress of pattern 2,5-S,S
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This pattern is still at the stage of making the polypeptide chain which

H
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is showed in the figure 12. The strategy is to build from the N
terminal: one side of Ethylene diamine is covered with the Cbz

Figure 12: 2,5-S,S-dibenzyl
2,5-S,Spolypeptide
polypeptide

protection and the other is left active to build the first peptide bond
with Boc-Phenylalanine-OSu. However, after putting the Cbz in, the

product needed to be separated from the matrix. In the first trial, the last NMR spectra did not
confirm the presence of Ethylene diamine having one protected side. There might be not enough
Ethylene diamine. In the contrary, the dry flash column chromatography in the second trial was
necessary because there was still some unprotected Ethylene diamine (its present was confirmed
when comparing TLC of fraction 2 with Ethylene diamine in MeOH.) The three fractions obtained
from the column are still being analyzed. Specifically, when performing the TLC comparing with
the solvent MeOH and the mixture of MeOH and Et2O, fraction 2 seems to contain the desired
product because it had different retention factor than the solvent’s. Fraction 1 had the retention
factor no different than the solvent. By that time fraction 3 was not dried yet to run TLC. Therefore,
fraction 2 must be analyzed first. A large amount of MeOH and Et2O was added in fraction 2 in
attempt to separate the desired product through crystallization. The NMR spectra of crystal from
fraction 2 and the original fraction 3 in DMSO have not been analyzed yet.
EXPERIMENTAL PROCEDURE
The four starting materials for the peptide synthesis in this project are Boc-Glycine-OSu (BocGly-OSu), L Phenylalanine-OBn (Phe-OBn), Boc-Phenylalanine-OSu (Boc-Phe-OSu), and
Ethylene diamine. Another goal must be achieved is to see if it is possible to make the desired
polypeptide chains with a minimum number of the pure, prepared and simple amino acids. All
amino acids used in this experiment were purchased from TCI America. Ethylene diamine and the
other chemicals were purchased from Sigma-Aldrich. The mass spectrometry analysis were
performed by using the ThermoElectron LTQ-Orbitrap Discovery high resolution mass
spectrometer with an Accela HPLC system. The H-NMR spectra were collected by using the
Bruker 400 MHz Avance II and spectrometer with the default probe is 5 mm BBFO. The use of
the corrosive Ethylene diamine, air sensitive and toxic chemicals TFA, BH3.THF, Benzyl

chloroformate and the operation of the Schlenk line followed the safety instruction of the
Chemistry Department of the Portland State University.
Pattern 2,8-S,S
Phe-OBn (10.3mmol) was mixed with Boc-Gly-OSu (10.5mmol) in the
solvent containing DCM (100mL) and iPr2Net (10.3 mmol.) The mixture
was stirred at the room temperature for 2 hours before getting a base wash
Figure 13: 2,8-S,S pattern
first peptide bond with Boc
and OBn protection

with supersaturated Na2CO3 and then extracted with DCM. After drying
off the solvent DCM, the intermediate product (5.44g) was collected and
an NMR analysis in CDCl3 was performed. The first peptide bond (figure

13) was built.
This intermediate product was mixed with a solvent containing DCM
(25mL) and TFA (25mL) in air free condition and stirred for 1 hour at
35oC. Another round with base wash and extraction with DCM was
performed. After drying, 6.04 g of solid was collected. This solid could
Figure 14: 2,8-S,S pattern
first peptide bond with
OBn protection

not dissolve in CDCl3, MeOH, H2O or MeCN with some drops of iPr2Net
but DMSO. No NMR nor mass spectrometry analysis was performed but
the expected structure is showed in figure 14.
The solid was dissolved in the solvent containing DMSO (150mL)
and iPr2Net (10.3mmol), mixed with Boc-Phe-OSu (10.3 mmol),
stirred at room temperature for one day. DMSO was removed by
rotovaping with the temperature increasing gradually from 25oC to

Figure 15: 2,8-S,S pattern first
and second peptide bonds with
Boc and OBn protection

75 oC. The white oily product could not dissolve in any available
organic solvents nor the mixture of them. No NMR analysis was
performed but the expected structure is showed in figure 15. This

intermediate formed a complex with Cu2+ and this complex dissolved in H2O and MeOH. Mass
spectrometry analysis on this complex was performed but there was no sign of the expected
molecule appeared on the mass spectrum.

Pattern 2,9-S,S
Ethylene diamine (3.30mmol) was mixed with Boc-Phe-OSu
(6.92mmol) in DCM (100mL) and stirred at room temperature for
1 hour before getting a base wash with Na2CO3 and extracted with
DCM to collect the organic layer. This layer was kept at 0oC for 5
Figure 16: 2,9-S,S dibenzyl poly
peptide with Boc protection groups

days before decanting the solvent.

1

H-NMR in MeOD was

performed. At this stage, the two desired peptide bonds were
formed (figure 16.)
To remove the Boc group, the intermediate product was mixed with
the solution of 1M acetyl chloride in dried MeOH and stirred in air
free condition at room temperature for 1 hour. After adding MeOH
Figure 17: 2,9-S,S dibenzyl
polypeptide

(50mL) and Et2O (100 mL), the sample was stored at 0oC for 10
days. After decanting the solvent, 0.7537g of light green yellow
crystal was collected. 1H-NMR in D2O was performed on the

sample of this crystal. At this point, the peptide chain (figure 17) was completed.
This crystal (0.4251g) was mixed with BH3.THF (30 mL) and
heated at 57oC for 1 day in inert atmospheric condition. When the
mixture cooled down to room temperature, MeOH (50mL) was
Figure 18: 2,9-S,S dibenzyl tetraamine

added by portion before stirring for 1 hour. Small portion of MeOH
was added until no bubble of H2 was observed. This indicated that

the Boron complex was deactivated. The solvent was removed. Four rounds of washing the solid
with MeOH (100mL each time) and removing the solvent were done and the product was an
orange-brown oil with very uncomfortable fishy smell was collected. This oil was mixed with HCl
solution (30mL, 1:10 v,v) and heated at 108 oC for 16 hours. KOH tablets were added by portion
until the pH reached 14. After the extraction with DCM, both aqueous and organic layers were
saved to analyze. The solvent was dried off from the organic layer and the 1H-NMR spectrum in
CDCl3 of this intermediate product was collected. Pure water was added in the aqueous layer until
the final volume equal to three times of the initial volume. This mixture was kept at -40oC for two
days before removing frozen solvent by freeze drying. The 1H-NMR spectrum in D2O and the

mass spectra in H2O/MeOH of this newly collected solid were obtained. The target molecules
(figure 18) was found in the aqueous layer.
Pattern 2,5-S,S
Two trials with different starting amount of Ethylene diamine and Benzyl chloroformate were
made as showed in table 2 below:
Trial

Ethylene diamine (mmol)

Benzyl chloroformate (mmol)

Ratio

1

28

14

2:1

2

58

14.5

4:1

Table 2: The summary amount of the starting materials in two trials

In both trials, the first goal was to add a Cbz protection group on one end of Ethylene diamine
(figure 19)
In trial 1, an air free condition was obtained by using the pressure equalizing
funnel drop. At 0oC, Ethylene diamine was added in DCM (100mL), then Benzyl
chloroformate was added and the mixture was stirred for 1 hour before the
Figure 19: Ethylene
diamine with Cbz
protection to build
the first peptide
bond of the 2,5-S,S
pattern

addition of H2O (15mL). After extracting and removing the solvent DCM from
the organic layer, the product was dissolved in CDCl3 to run 1H-NMR but it was
not the desired molecule.
In trial 2, after Ethylene diamine and Benzyl chloroformate got mixing in the

same condition in the trial 1, the mixture was stirred overnight. Cu(OH)2CuCO3 (14.5mmol) in
H2O (20mL) was slowly added and stirred. When the pH was 12, the organic layer was extracted
with DCM and dried. 1H-NMR analysis in MeOD was performed. TLC comparing with Ethylene
diamine was performed. Dry flash column chromatography was performed on the sample with the
first wash was Et2O and three fractions in MeOH. When all fractions dried, TLC tests comparing
with MeOH, mixture of MeOH (35%) and Et2O (65%), and Ethylene diamine were performed to
find the fraction containing the most amount of the product. A significant larger amount of the
solvent containing MeOH and Et2O (ratio 1:2) was added in the fraction 2. After one day, the
solvent was decanted to collect the crystalized solid. 1H-NMR in DMSO of the crystalized fraction
2 and the fraction 3 were performed.

ACKNOWLEDGEMENT
The author would like to thank Dr. Mark Woods and the BUILD EXITO Program for giving her
such a precious opportunity to participate in this wonderful research. The author also appreciates
the supports from all of the graduate students in Dr. Woods’ lab.

REFERENCES
[1] Brenner, D.J; Hall, E.J. New England Journal of Medicine 2007, 357, 2277
[2] de Gonzalez, A. B; Darby, S. The Lancet 2004, 363,345.
[3] Rothkamm, K.; Barloop, S.; Skerhdar, J.; Fernie, P; Goh, V. Radiology 2007, 242,244.
[4] R. Bitar et al; MR Pulse Sequences: What Every Radiologist Wants to Know but Is Afraid to
Ask. Radiographics 2006.
[5] Loncin, M. F; Desreux, J.F and Merciny, E. Inorganic Chemistry 1986 25 (15), 2646-2648
[6] E.J. Blink; MRI principles. 2004
[7] C. Westbrook et al; MRI in Practice. 2011
[8] Rogosnitzky, M. & Branch, S. Gadolinium-based contrast agent toxicity: a review of known

and proposed mechanisms. Biometals 29, 2016, 365–376
[9] Woods, M.; Kovacs, Z.; Kiraly, R.; Brücher, E.; Zhang, S.; & Sherry, A. Solution dynamics and
stability of lanthanide(III) (S)-2-(p-nitrobenzyl)DOTA complexes. 2004 Inorganic Chemistry, 43(9),
2845-51.
[10] Payne, K. & Woods, M. Isomerism in benzyl-DOTA derived bifunctional chelators: Implications for
molecular imaging. Bioconjugate Chemistry, 2015, 26(2), 338-44.
[11] Rust, L; Payne, K; Carniato, F; Botta, M; and Woods, M. Differences in the Relaxometric
Properties of Regioisomeric Benzyl-DOTA Bifunctional Chelators: Implications for Molecular Imaging.
Bioconjugate Chemistry 2019 30 (5), 1530-1538
[12] Weisman, G. R.; Reed, D. P. J. Org. Chem. 1996, 61, 5186; (b) Correction: J. Org.

Chem. 1997, 62, 4548.

